Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Eli Lilly said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking Wegovy and Zepbound injections in a late-stage trial ...

If you have obesity and are curious whether a weight loss medication could help you improve your health, there are a number of weight loss pills on the market to consider, both old and new.

The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their ...

Dec 8 (Reuters) - Structure Therapeutics (GPCR.O), opens new tab said on Monday its obesity pill showed weight loss of up to 11.3% after 36 weeks of treatment in a mid-stage study, driving the company ...

Truth matters. Community matters. Your support makes both possible. LAist is one of the few places where news remains independent and free from political and corporate influence. Stand up for truth ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

The global weight-loss drug market is entering a new phase, driven by the arrival of oral options, looming generic rivals and falling U.S. prices for blockbuster treatments from Eli Lilly and Novo ...

In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster injections ...

LONDON, Feb 6 (Reuters) - Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking debate about the legality of the move and threatening ...